Water not required with Ortho's VITROS Micro Slides and Systems Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, has received the CII National Award for Excellence in Water Management 2019 for its proprietary VITROS Micro Slide technology in the category of Innovative Water Saving Product.The award, presented by the Confederation of Indian Industry, honors a technology for processing test samples in medical labs that distinguishes Ortho from its competitors.This eliminates the risk that poor water quality could impact test results."We're thrilled with this recognition because it highlights the uniqueness of MicroSlides and the value of eliminating water from the clinical lab testing process," said Anand Pande, head of Ortho's ASPAC region, which includes India."Heidi Casaletto, Ortho's head of portfolio strategy and marketing, noted in a video on Ortho's website that being waterless makes Ortho MicroSlides and VITROS Systems ideal during natural disasters and other emergencies where infrastructure may be disrupted."About the Confederation of Indian IndustryThe Confederation of Indian Industry (CII) works to create and sustain an environment conducive to the development of India, partnering industry, government and civil society through advisory and consultative processes.CII is a non-government, not-for-profit, industry-led and industry-managed organization, playing a proactive role in India's development process.About Ortho's VITROS SystemsThe VITROS Chemistry, Immunodiagnostics and Integrated Systems from Ortho Clinical Diagnostics is a portfolio of products and patented enabling technologies which help clinical laboratories diagnose, monitor and treat disease.
Ortho’s latest Covid-19 can run up to 130 tests per hour and immediately help hospitals and reference labs address testing backlogs, supply shortages, and delayed resultsOrtho Clinical Diagnostics has launched VITROS SARS-CoV-2 antigen test on their VITROS 3600, VITROS 5600/ VITROS XT7600 systems, designed to detect active infection, which has the potential to supplement the available Covid testing tools.A press release said that Ortho’s latest Covid-19 can run up to 130 tests per hour and immediately help hospitals and reference labs address testing backlogs, supply shortages, and delayed results.The clinical diagnostic manufacturer said the company has obtained approval for emergency use from the Indian regulator Central Drugs Standard Control Organisation (CDSCO).“Even as vaccine inoculation programs roll out, mass-scale testing remains an essential tool in fighting Covid-19.Our accurate, high-volume Covid-19 antigen test can play a pivotal role in the global response to this virus,” said Chris Smith, Chairman and CEO, Ortho Clinical Diagnostics.The antigen test is an alternative to real-time PCR testing, which, although highly sensitive, can be expensive and requires long processing times during testing surges.The antigen tests deliver fast, high-volume testing for active infection with excellent specificity and sensitivity, he added.
At a time when people are growing more and more restless with prolonged life in isolation, and people of all ages are yearning to return to social life with loved ones, Ortho Clinical Diagnostics now offers the VITROS SARS-CoV-2 Antigen Test on their systems, designed to detect active infection, can be a vital additional supplement to current testing scenarios.With utility for mass-scale testing and same-day results for labs, Ortho’s latest COVID-19 solution can run up to 130 tests per hour and immediately help hospitals and reference labs address testing backlogs, supply shortages, and delayed results.Thus, providing fast and accurate results.Ortho’s COVID-19 antigen test was the first high-volume test to receive Food and Drug Administration (FDA) Emergency Use Authorization (EUA) in the U.S.In India, CDSCO also has given approval for emergency use.“As the pandemic continues to devastate our communities and economy, laboratory professionals have been working under extraordinary circumstances to deliver critical COVID-19 testing data to patients, clinicians and communities,” Chairman & CEO, Ortho Clinical Diagnostics Chris Smith said.He added, “Even as vaccine inoculation programs roll out, mass-scale testing remains an essential tool in fighting COVID-19.Ortho’s accurate, high-volume COVID-19 antigen test can play a pivotal role in the global response to this virus.” https://pynr.in/article/ortho-s-vitros-r-sars-cov-2-antigen-test-is-now-available-for-accurate
Aligned with its mission to improve and save lives with diagnostics, Ortho Clinical Diagnostics today announced it is launching to market its SARS-CoV-2 (COVID-19/coronavirus) antibody test—the VITROS® Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack.Testing kits are expected to be available in a few weeks.Ortho followed the guidelines established by the U.S. Food and Drug Administration’s (FDA) Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency.“The unprecedented nature of this rapidly spreading virus required an immediate response from the diagnostics industry, and Ortho followed through on its commitment to help develop better ways to treat patients and provide robust data to help manage COVID-19,” said Chris Smith, chief executive officer.“At Ortho Clinical Diagnostics, the patient is at the heart of everything we do—because we believe behind every test is a life.”The VITROS® Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack detects antibodies (including IgG and IgM) to SARS-CoV-2 that can be used to detect immune response to the virus.“It’s inspiring to think of the good the healthcare community can do by advancing the learning about this virus.”The test will run on Ortho’s flagship analyzer, the VITROS® XT 7600 Integrated System, the VITROS® 3600 Immunodiagnostic System, the VITROS® 5600 Integrated System and VITROS® ECi/ECiQ Immunodiagnostic Systems and can process approximately 150 tests in an hour.The systems are designed to remove barriers and adaptable for non-traditional laboratory environments because they don’t require an external water supply to run and are already installed in more than 1,000 hospital and reference labs throughout the United States.